SATB2 and invasive carcinoma: Three of 25 (12%) CD-SBNs (1 conventional type invasive carcinoma and 2 conventional type dysplasias; 1 dysplasia was adjacent to SATB2 positive invasive carcinoma) were SATB2 positive and all SATB2-positive CD-SBNs showed CDH17 expression, whereas no CLDN18 expression was identified.